Nigrostriatal Dopamine Terminals In Parkinson'S Disease is a cell type relevant to neurodegenerative disease research. This page covers its role in brain function, involvement in disease processes, and significance for therapeutic strategies.
Nigrostriatal dopamine neurons project from the substantia nigra pars compacta (SNc) to the dorsal striatum (caudate and putamen). These terminals are the primary site of neurodegeneration in PD, leading to the characteristic motor symptoms.
- Tier organization: Dorsolateral (more vulnerable) vs ventromedial
- Cell types: Dopaminergic neurons (A9 group)
- Connectivity: Dense projections to striatum
- Dorsolateral striatum: Motor control regions
- Dorsomedial striatum: Associative regions
- Patch/matrix compartments: Differential innervation
- Synaptic architecture: Axospinous synapses
- Initiation of movement
- Motor learning
- Habit formation
- Action selection
- Pacemaker activity: Autonomous firing
- Burst firing: Reward prediction signals
- Tonic firing: Background dopamine release
- Dopamine release: Calcium-dependent exocytosis
- D1 receptors: Direct pathway activation
- D2 receptors: Indirect pathway inhibition
- Modulation: via D3, D4, D5 receptors
- Mitochondrial complex I deficiency
- Oxidative stress accumulation
- Alpha-synuclein aggregation
- Neuroinflammation initiation
- Dorsolateral SNc → ventromedial
- Putamen → caudate
- Caudor → progression
- Axonal transport defects
- Synaptic vesicle dysfunction
- Endoplasmic reticulum stress
- Lysosomal/autophagy dysfunction
- L-DOPA: Dopamine precursor
- Dopamine agonists: Direct receptor activation
- MAO-B inhibitors: Prevent dopamine breakdown
- Neurotrophic factors: GDNF, BDNF
- Alpha-synuclein targeting: Immunotherapy, aggregation inhibitors
- Mitochondrial protectants: CoQ10, creatine
- Cell replacement: Stem cell therapy
- DAT imaging: Terminal density measurement
- CSF biomarkers: Neurofilament light chain
- Clinical measures: Motor scores, PET/SPECT
The study of Nigrostriatal Dopamine Terminals In Parkinson'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Kalia LV, Lang AE. (2015). Parkinson's disease. Lancet.
- Surmeier DJ, et al. (2017). Neuronal vulnerability in PD. Nat Neurosci.
- Poewe W, et al. (2017). Parkinson disease. Nat Rev Dis Primers.